Regeneron Executive and Leadership Team

Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, directs the overarching corporate strategy and long-term vision for the biotechnology enterprise. Overseeing the discovery and commercialization of innovative medicines, the Co-Chair, President & Chief Executive Officer ensures alignment between scientific research and market needs. This leadership role involves managing complex stakeholder relationships and guiding the organization through competitive pharmaceutical landscapes. By prioritizing high-impact therapeutic development, Leonard Schleifer directly influences the company's ability to address serious diseases like cancer and inflammatory disorders. The Co-Chair, President & Chief Executive Officer maintains a focus on sustainable growth while fostering a culture of scientific excellence. Through strategic oversight of global operations, Schleifer secures the necessary resources to advance the pipeline, ultimately driving the mission to deliver life-changing treatments to patients across diverse international markets.

Leonard Schleifer, the Board co-Chair, President & Chief Executive Officer at Regeneron, governs the board-level initiatives and executive management of the biotechnology firm. Focusing on the intersection of corporate governance and drug development, the Board co-Chair, President & Chief Executive Officer architects the strategic framework for commercializing proprietary technologies. This role requires constant interaction with the board to ensure compliance and operational efficiency across all therapeutic areas. By steering the company toward breakthrough innovations in eye diseases and rare conditions, Leonard Schleifer shapes the future of the pharmaceutical portfolio. The Board co-Chair, President & Chief Executive Officer manages the executive team to maintain high standards of scientific integrity and financial performance. Through rigorous oversight of the company's market position, Schleifer ensures that the organization remains at the forefront of biotechnology, consistently delivering value to patients and shareholders through advanced medical solutions.

George Yancopoulos, the President & Scientific Office Chief & Co-Founder at Regeneron, architects the core scientific research and development programs that define the company's biotechnology portfolio. Overseeing the discovery of innovative medicines for serious diseases, the President & Scientific Office Chief & Co-Founder drives the proprietary technologies that enable breakthroughs in cancer and inflammatory disorders. This leadership role involves guiding the research teams and collaborating with the executive leadership to translate scientific discoveries into commercial products. By fostering a culture of rigorous inquiry, George Yancopoulos ensures that the company remains a leader in the pharmaceutical industry. The President & Scientific Office Chief & Co-Founder manages the scientific strategy to address unmet medical needs through advanced science. Through the application of proprietary platforms, Yancopoulos accelerates the development of life-changing treatments, ensuring that the company's scientific output consistently aligns with its mission to improve patient health outcomes on a global scale.

Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, manages the organizational design and talent acquisition strategies essential for biotechnology success. Overseeing the alignment of human capital with scientific objectives, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources ensures that the workforce possesses the specialized skills required for drug discovery. This leadership role involves coordinating with the Chief of Staff to streamline internal communications and executive workflows. By fostering a high-performance culture, Erin Rohr directly supports the development of life-changing treatments for serious diseases. The Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources implements initiatives that drive employee engagement and retention across the company's research facilities. Through strategic workforce planning, Rohr optimizes the organizational structure to support the company's mission of delivering innovative medicines to patients globally.

Wrechelle Nantes, the Executive Assistant To the Chief Human Resources Officer at Regeneron, coordinates the administrative operations and strategic scheduling for the human resources department. Overseeing the flow of information between the Chief Human Resources Officer and the broader leadership team, the Executive Assistant To the Chief Human Resources Officer ensures that critical personnel initiatives receive timely attention. This role involves managing complex calendars and facilitating communication across various departments to support the company's biotechnology mission. By organizing key meetings and tracking departmental goals, Wrechelle Nantes enables the leadership to focus on talent development and organizational health. The Executive Assistant To the Chief Human Resources Officer maintains the operational rhythm necessary for the HR function to support the discovery and commercialization of innovative medicines. Through meticulous attention to detail, Nantes facilitates the smooth execution of human resources strategies that underpin the company's ability to address serious diseases.

Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, directs the operational frameworks governing regulatory compliance and patient safety. Overseeing the integration of quality standards into the drug development lifecycle, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality ensures that all innovative medicines meet rigorous safety benchmarks. This leadership role involves coordinating with the Executive VP to align regulatory strategies with the company's broader scientific goals. By managing the operational strategy, Kim Brenner facilitates the efficient movement of treatments from the laboratory to the patient. The Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality maintains oversight of quality assurance processes to protect the integrity of the company's therapeutic portfolio. Through strategic planning, Brenner ensures that the organization adheres to global regulatory requirements while advancing life-changing medical solutions.

Vicky Elsa, the 營售總監 at Regeneron, directs the commercial sales strategies and market expansion efforts for the company's therapeutic portfolio. Overseeing the distribution and market penetration of innovative medicines, the 營售總監 ensures that life-changing treatments reach patients suffering from serious diseases. This leadership role involves analyzing market trends and coordinating with regional teams to optimize sales performance across diverse territories. By implementing targeted commercial initiatives, Vicky Elsa drives the revenue growth necessary to support ongoing research and development. The 營售總監 manages the sales operations to ensure that the company's products are effectively positioned against competitors in the pharmaceutical market. Through strategic engagement with healthcare providers and stakeholders, Elsa facilitates the adoption of new therapies. By focusing on operational excellence in sales, the 營售總監 directly contributes to the company's mission of delivering advanced medical solutions to patients in need of effective treatments.